SCHEDULE: Vanguard Discloses 5.19% Stake in Crinetics Pharmaceuticals

Vanguard Capital Management has reported beneficial ownership of 5.19% of Crinetics Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 5,440,646 shares of Crinetics Pharmaceuticals Inc. common stock.
• This holding represents 5.19% of the total class of securities.
• The filing indicates that Vanguard has sole dispositive power over these shares and sole voting power over 766,711 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a major institutional investor like Vanguard taking a significant stake often implies a belief in the company's future value, though the filing itself is purely a disclosure.

Positives

• Vanguard's significant stake suggests confidence in Crinetics Pharmaceuticals' long-term prospects.
• The filing confirms that Vanguard's holdings are for ordinary course of business, not for control, which is a standard disclosure for institutional investors.

Negatives

• The filing does not contain any negative financial or operational information about Crinetics Pharmaceuticals.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks related to Crinetics Pharmaceuticals' operations or market position.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Crinetics Pharmaceuticals. It is a disclosure of ownership by Vanguard.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major institutional investor like Vanguard, indicating a significant ownership stake (over 5%), often signals a positive view on the company's growth potential within the biotechnology or pharmaceutical sector. This level of investment can attract further institutional interest.

Stakeholder Impact

• Shareholders may view Vanguard's increased stake as a positive signal, potentially leading to increased investor confidence and share price stability or appreciation.
• Employees and management of Crinetics Pharmaceuticals may see this as validation of their strategy, potentially boosting morale.

Next Steps

• Vanguard will continue to monitor its investment in Crinetics Pharmaceuticals and may adjust its holdings based on market conditions and company performance.
• Crinetics Pharmaceuticals will continue its business operations as disclosed in its other SEC filings.

Key Dates

Recommendation

This filing is a disclosure of ownership by a major institutional investor and does not provide operational or financial results of Crinetics Pharmaceuticals. While Vanguard's investment is a positive signal, a 'hold' recommendation is appropriate without further performance data from the company itself.

Keywords

Crinetics Pharmaceuticals, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing